Abstract
Predicting Discontinuation of Docetaxel Treatment for Metastatic Castration-Resistant Prostate Cancer (mCRPC) With Hill-Climbing and Random Forest
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have